Abstract
This article discusses issues related to the role of biotransformation or metabolism of antipsychotics (APs) in the liver. There are three phases of APs metabolism. Cytochrome P450 monooxygenase, an oxidase with mixed functions, plays a key role in the biotransformation of most APs, participating in the first phase of metabolism. The functional activity of cytochrome P450 enzymes depends on the carriage of single nucleotide variants (SNVs) of the genes encoding these enzymes, as well as on drug-drug interactions. The functional activity of cytochrome P450 enzymes may affect the efficacy and safety of the use of APs. It is important for a practicing psychiatrist to know the pathways of APs oxidation to prevent adverse drug reactions (ADRs) and unwanted drug-drug interactions, which will subsequently increase the efficacy and safety of AP therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
